Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaccine with Poly-ICLC
- Development stage
- Unknown
- Lead developer
- Oncovir
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Subcutaneous
01
Overview
A "vaccine with Poly-ICLC" refers to a therapeutic cancer or infectious disease vaccine formulation that includes the immunostimulatory adjuvant Poly-ICLC (polyinosinic-polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose). This agent acts as a synthetic double-stranded RNA analog that mimics viral infection to activate innate immune responses via Toll-like receptor 3 (TLR3) and MDA5 pathways. In these vaccines, tumor-specific antigens (such as peptides or neoantigens) are combined with Poly-ICLC to enhance antigen presentation and stimulate robust adaptive immune responses against tumor cells. The combination is under investigation for various cancers including melanoma, glioblastoma, malignant pleural mesothelioma, biliary tract cancers, lymphoma subtypes, metastatic breast cancer (MBC), head and neck squamous cell carcinoma (HNSCC), among others[1][2][4][7]. The vaccines are typically administered intratumorally or subcutaneously.
- Brand names
- Hiltonol
- Other names
- polyinosinic-polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulosePoly ICLC vaccinepeptide-based cancer vaccine with Poly-ICLC
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on vaccine with Poly-ICLC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaccine with Poly-ICLC.